BD Launches Elyra Thulium Fiber Laser System for Kidney Stone Care
BD (Becton, Dickinson and Company) has launched the Elyra Thulium Fiber Laser (TFL) System, an advanced medical device designed to improve efficiency and versatility in kidney stone management and soft tissue procedures. This new system, available in two configurations, uses advanced TFL technology to streamline kidney stone treatment and boasts an intuitive user interface and rapid startup. Despite the innovation, BD's stock saw a slight dip, but the company anticipates long-term growth by strengthening its urologic stone management portfolio in a growing market.
Intuitive readies 100 updates and improvements for da Vinci 5
Intuitive is preparing to roll out over 100 updates and user experience improvements for its da Vinci 5 surgical robot, starting in June in the U.S. These enhancements aim to boost communication between remote and on-site physicians, simplify access, and improve educational opportunities. The updates also include increasing the number of uses for several force-feedback instruments, which could reduce per-procedure costs amidst growing competition in the robotic surgery market.
Zacks Industry Outlook Highlights Electromed, Globus Medical and Intuitive Surgical
This Zacks Industry Outlook highlights Electromed (ELMD), Globus Medical (GMED), and Intuitive Surgical (ISRG) as key players poised to thrive in the medical instruments industry, driven by the increasing adoption of generative AI. The article details how AI is transforming medical diagnostics, surgeries, and drug development, despite industry challenges such as global economic slowdowns and inflation. It also discusses M&A trends and the current market valuation for medical instrument stocks.
Pzena Investment Management LLC Reduces Stock Holdings in Medtronic PLC $MDT
Pzena Investment Management LLC significantly cut its stake in Medtronic PLC by 45.7% in the fourth quarter, selling over 2.7 million shares but still holding 3.22 million shares valued at approximately $309.2 million. Medtronic is receiving mixed analyst sentiment, with some downgrades and lower price targets, despite a "Moderate Buy" consensus and an average target price of $106.45. The company recently announced a $650 million acquisition of SPR Therapeutics to expand its chronic pain neuromodulation portfolio, a move that has drawn some market concerns regarding costs and execution risks.
Zimmer Biomet Holdings, Inc. $ZBH Stake Cut by Heritage Investors Management Corp
Heritage Investors Management Corp reduced its stake in Zimmer Biomet Holdings, Inc. ($ZBH) by 8.3% in the fourth quarter, selling 12,149 shares. This leaves them with 133,845 shares valued at approximately $12.0 million. Despite mixed institutional activity and a consensus "Hold" rating from analysts, Zimmer Biomet reported strong quarterly results, exceeding EPS and revenue expectations.
Intuitive Surgical Inc. stock underperforms Thursday when compared to competitors
Intuitive Surgical Inc. (ISRG) stock fell by 2.06% on Thursday, closing at $439.80, despite a generally favorable trading session for the broader market. This decline broke a three-day winning streak for the company, which underperformed compared to the S&P 500 Index and the Dow Jones Industrial Average.
Intuitive Surgical stock (US46120E6023): insider sale and long?term growth story in focus
Intuitive Surgical (ISRG) remains a key player in robotic-assisted surgery, despite a recent small insider sale and stock price volatility in early 2026. The company generates revenue from selling da Vinci systems and recurring charges for instruments and services, maintaining a strong market position through technological leadership and a broad training ecosystem. Investors are watching competitive pressures, regulatory changes, and valuation closely in this high-growth medical technology sector.
Intuitive Unveils Da Vinci 5 Ecosystem Enhancements
Intuitive has announced over 100 enhancements to its da Vinci 5 robotic surgical system and its supporting ecosystem, including extended-use Force Feedback instruments and improved security features. These updates aim to boost product reliability, enhance surgeon experience through features like real-time telepresence and mobile login, and streamline surgical workflows with new simulation exercises and multi-arm targeting. The changes also reflect Intuitive's commitment to advancing minimally invasive care and improving patient outcomes.
Intuitive announces da Vinci 5 updates, extended instrument use By Investing.com
Intuitive Surgical has announced significant updates to its da Vinci 5 robotic surgical system, including over 100 enhancements for U.S. users starting in June and global availability pending regulatory clearances. These updates feature improvements to Intuitive Telepresence for remote observation, new digital measurement tools, and extended use capabilities for several Force Feedback instruments. The company, valued at $159 billion with strong revenue growth, also reported that over 1,400 da Vinci 5 systems are installed globally, performing more than 380,000 procedures.
Robotic surgery gets telepresence, force-sensing tools in Intuitive upgrade
Intuitive (Nasdaq: ISRG) announced significant innovations for its da Vinci 5 robotic surgical system, including enhanced telepresence capabilities, expanded uses for Force Feedback instruments, and improved product reliability and security. These updates aim to advance patient care, optimize surgeon experience, and reduce costs, with features like a full-OR telepresence camera, mobile console login, new training modules, and an anticipated increase in instrument uses by 2027. The company also highlighted strong da Vinci 5 adoption, with over 1,400 systems installed globally and 380,000 procedures performed, along with a guaranteed 98% uptime exceeding 99% actual performance.
Intuitive Announces Innovations to Advance Quintuple Aim
Intuitive Surgical announced new innovations to advance the Quintuple Aim in healthcare, focusing on improved patient care, enhanced surgeon experience, increased access to minimally invasive care, and reduced costs. The updates include telepresence enhancements for da Vinci 5, extended-use Force Feedback instruments, and advancements in product reliability and security. These innovations are designed to strengthen collaboration, connectivity, and outcomes across the surgical ecosystem.
IFP Advisors Inc Boosts Stake in Medtronic PLC $MDT
IFP Advisors Inc increased its stake in Medtronic PLC by 33.4% in the fourth quarter, now owning 57,287 shares valued at $5,503,000. Other institutional investors also adjusted their positions in Medtronic, which has a current market cap of $100.26 billion and recently announced a quarterly dividend. The medical technology company's stock is trading down 0.6% and has received a "Moderate Buy" consensus rating from analysts.
West Pharmaceutical Services returns to full operations following cybersecurity attack
West Pharmaceutical Services announced that it has fully restored operations across all its sites after experiencing a cybersecurity attack earlier this month. The company believes the incident will not materially impact its 2026 financial outlook, despite data theft and system lockouts. While investigation continues, no further unauthorized access has been detected, and analysts remain encouraged by the company's quick recovery.
Intuitive surgical EVP Brosius sells $23,463 in company stock
Mark Brosius, EVP at Intuitive Surgical Inc., sold 54 shares of company stock in three transactions totaling $23,463 between May 18 and May 20, 2026. These sales occurred while the stock was near its 52-week low and were conducted under a pre-arranged trading plan. Despite the sales, analysts have revised earnings estimates upwards for the company, and several firms maintained an Overweight rating due to strong performance.
Insider Sell: Mark Brosius Sells Shares of Intuitive Surgical In
Mark Brosius, Executive Vice President & Chief Manufacturing and Supply Chain Officer at Intuitive Surgical Inc (ISRG), sold 54 shares of the company on May 20, 2026. This transaction brings his total sales over the past year to 11,821 shares, with no purchases. Intuitive Surgical Inc's stock is currently trading at $434.52 and is considered modestly undervalued with a price-to-GF-Value ratio of 0.73.
Intuitive Surgical (NASDAQ: ISRG) EVP sells 54 shares via Rule 10b5-1 plan
Mark Brosius, EVP and Chief Manufacturing and Supply Chain Officer at Intuitive Surgical (NASDAQ: ISRG), sold 54 shares of company common stock in three separate transactions between May 18 and May 20, 2026, totaling approximately $23,464. These sales were pre-arranged under a Rule 10b5-1 trading plan set to expire in February 2027. Following these transactions, Brosius directly holds 1,559 shares, indicating a routine, non-discretionary sale with limited signaling impact on the company's prospects.
West Pharma says fully operational after cyberattack, sees no hit to 2026 forecast
West Pharmaceutical Services has announced that it has fully restored operations after a cybersecurity attack earlier this month. The company does not anticipate any material impact on its 2026 financial outlook and continues its investigation, having found no further unauthorized access. Analysts are encouraged by the company's quick return to normal operations and ability to offset disruptions.
Intuitive Surgical Inc. stock outperforms competitors on strong trading day
Intuitive Surgical Inc. (ISRG) shares rose 1.69% to $449.03 on Wednesday, marking its third consecutive day of gains. The stock's performance outpaced the broader market, with the S&P 500 Index and Dow Jones Industrial Average also seeing increases. This positive trading session contributed to a favorable day for the market overall.
Intuitive Surgical stock (US46120E6023): da Vinci maker in focus after latest earnings and analyst u
Intuitive Surgical remains a key focus for investors following its recent quarterly earnings report and subsequent analyst comments. The company, known for its da Vinci robotic surgery systems, reported double-digit procedure growth and increased revenue, while also emphasizing ongoing investments in R&D and regulatory advancements. Investors are closely monitoring its procedure growth, system launches, and margins as it navigates a competitive medical technology market.
PACB & Blank Bio Partner to Advance RNA Foundation Models in Oncology
Pacific Biosciences (PACB) has partnered with Blank Bio, an AI research company, to advance RNA foundation models for precision oncology, including a $7.2 million seed investment. Blank Bio will utilize PacBio’s HiFi long-read sequencing technology to generate RNA sequencing data from tumor samples, with the goal of improving biomarker discovery, diagnostics, and clinical trial design. This collaboration aims to strengthen PacBio's position in the oncology market and expand the application of its technology in AI-driven precision medicine.
T. ROWE PRICE EXAMINES LEADERSHIP, CULTURE AND THE EVOLVING ROLE OF CAPITAL MARKETS WITH GOLDMAN SACHS CEO DAVID SOLOMON
T. Rowe Price's "The Angle" podcast features a discussion with Goldman Sachs CEO David Solomon about leadership, institutional culture, and the evolving role of capital markets. Hosted by Eric Veiel, the episode delves into how businesses adapt to shifting economic conditions and the qualities of durable leadership in a dynamic environment. This is part of a C-suite podcast series exploring insights from various industry leaders.
Medtronic PLC $MDT is Lazard Freres Gestion S.A.S.'s 10th Largest Position
Lazard Freres Gestion S.A.S. has significantly increased its stake in Medtronic PLC, making it the 10th largest position in its investment portfolio. Medtronic reported strong quarterly results, surpassing analyst expectations with $1.36 EPS and $9.02 billion in revenue, and continues to be an attractive income stock with a 47-year streak of dividend increases. The company's revenue rose 5.8% year over year, and it maintains a moderate buy rating from analysts with an average price target of $107.80.
Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Receives Consensus Rating of "Hold" from Analysts
Analysts have given Zimmer Biomet Holdings, Inc. (NYSE:ZBH) a consensus "Hold" rating, based on coverage from 23 research firms with an average 12-month price target of $102.80. The company recently exceeded earnings expectations, reporting a 9.3% year-over-year revenue increase and raising its FY2026 EPS guidance. Zimmer Biomet also continues to reward shareholders with a quarterly dividend of $0.24 per share, representing an annual yield of approximately 1.1%.
Fideuram Intesa Sanpaolo Private Banking S.P.A. Invests $8.37 Million in Medtronic PLC $MDT
Fideuram Intesa Sanpaolo Private Banking S.P.A. has acquired a new stake of 87,140 shares in Medtronic PLC, valued at approximately $8.37 million. This investment highlights continued institutional interest in Medtronic, with 82.06% of the stock held by institutions and hedge funds. The medical technology company recently reported strong quarterly earnings, exceeding analyst expectations with $1.36 EPS on $9.02 billion in revenue, and maintains a "Moderate Buy" consensus rating among analysts.
Gabelli Funds LLC Boosts Holdings in Zimmer Biomet Holdings, Inc. $ZBH
Gabelli Funds LLC increased its stake in Zimmer Biomet Holdings, Inc. by 12.4% in the fourth quarter, bringing its total to 130,350 shares valued at $11.7 million. Zimmer Biomet reported stronger-than-expected quarterly results, with $2.09 EPS on revenue of $2.09 billion, up 9.3% year-over-year. While analyst sentiment is mixed with an average "Hold" rating and a price target of $102.80, the company recently announced a quarterly dividend of $0.24 per share.
2 Healthcare Stocks Worth Investigating and 1 Facing Headwinds
This article analyzes three healthcare stocks, recommending two for investigation and one to potentially avoid. Moderna is highlighted as a stock to sell due to declining sales, profitability, and free cash flow margin. Conversely, Intuitive Surgical is presented as a strong watch due to robust revenue growth, share buybacks, and a healthy free cash flow margin, while BrightSpring Health Services is also recommended for its impressive revenue growth, large revenue base, and strong future growth estimates.
Investors heavily search Intuitive Surgical, Inc. (ISRG): Here is what you need to know
The article indicates that Intuitive Surgical, Inc. (ISRG) is a frequently searched stock by investors. It suggests that this high search volume implies investor interest in understanding the company's current status and future prospects. However, the provided content is incomplete, so no further details can be extracted.
Silver Economy Investing: Why the Healthcare Giants Are in Focus
The article discusses the "Silver Economy," highlighting how the rapidly aging global population is creating significant growth opportunities in the healthcare sector. It emphasizes how major healthcare companies like Eli Lilly, Tandem Diabetes Care, Intuitive Surgical, and ResMed are capitalizing on this demographic shift through innovation in areas such as obesity, diabetes, robotic surgery, and sleep health. The piece also details specific initiatives by these companies and outlines the financial resilience of the healthcare sector as an investment.
Robotics expert Brian Miller on product development, AI and what he learned at Intuitive
Brian Miller, former Intuitive EVP and chief digital officer, shares insights on product development, understanding customer needs, and the role of AI in surgical robotics, drawing from his extensive experience. Now CEO of Sovato, Miller emphasizes the importance of critical thinking, deep customer observation, and responsible use of AI and data in medical device innovation. He also touches on making the most of intraprocedural data and addressing potential "deskilling" concerns with advanced technologies.
Investors heavily search Intuitive Surgical, Inc. (ISRG): Here is what you need to know
This article mentions that investors are actively searching for information on Intuitive Surgical, Inc. (ISRG). It implies that the content would provide key details about the company to meet this investor interest.
Intuitive Surgical stock (US46120E6023): robot-assisted surgery leader in focus after latest quarterly figures
Intuitive Surgical recently reported its latest quarterly results, highlighting continued growth in its da Vinci robotic surgical system procedures, an expanding installed base, and increasing recurring revenue streams. The company's business model relies on capital sales of its da Vinci systems combined with recurring revenue from instruments, accessories, and service contracts. Intuitive Surgical remains a key player in robot-assisted surgery, but its performance is influenced by hospital capital budgets, procedure trends, and competitive dynamics.
DXCM to Launch Dexcom Flex CGM System for Type 2 Diabetes in Germany
DexCom (DXCM) is set to launch its new Dexcom Flex continuous glucose monitoring (CGM) system in Germany, targeting adults with Type 2 diabetes who are not on intensive insulin therapy. This move aims to broaden access to CGM technology, aligning with the company's strategy to enhance personalized care for a wider patient population. The launch is expected to strengthen DexCom's market position, support long-term revenue growth, and capitalize on the expanding diabetes technology market.
Intuitive Surgical Price Target Cut to $520.00/Share From $650.00 by B of A Securities
B of A Securities has reduced its price target for Intuitive Surgical (ISRG) shares from $650.00 to $520.00. Despite this significant cut, the firm maintained a Buy rating on the stock, indicating continued confidence in the company's long-term prospects. This adjustment reflects an updated valuation by the analyst, likely in response to recent market conditions or company performance.
Intuitive Surgical stock (US46120E6023): robot-assisted surgery leader after latest earnings
Intuitive Surgical, the maker of the Da Vinci robotic surgery systems, reported solid revenue growth and increased procedure volumes in its latest quarterly update, despite share price volatility. The company's business model relies on the sale of specialized instruments and accessories for its systems, which provides a recurring revenue stream, alongside system sales and service contracts. Intuitive Surgical continues to expand its installed base and procedure offerings, with significant growth in international markets.
Zimmer Biomet Holdings, Inc. $ZBH Shares Sold by Independent Advisor Alliance
Independent Advisor Alliance significantly reduced its stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 85.5% in the fourth quarter. Despite this, Zimmer Biomet reported strong quarterly results, beating analyst estimates for EPS and revenue, and institutional investors collectively own 88.89% of the company's stock. The company also announced a quarterly dividend and analysts currently have a "Hold" rating with an average target price of $102.80.
Intuitive Surgical Inc Stock (ISRG) Moved Up by 3.76% on May 18: A Full Analysis
Intuitive Surgical Inc. (ISRG) stock increased by 3.76% on May 18th, driven by strong Q1 2026 financial results, which reported $2.77 billion in revenue and a 23% year-over-year increase. The company also raised its 2026 procedure guidance due to the success of its da Vinci 5 platform. Analysts maintain a "Moderate Buy" rating with a consensus price target of $583.45, reflecting positive market sentiment despite some technical indicators suggesting caution.
Intuitive Surgical Inc. stock outperforms competitors on strong trading day
Shares of Intuitive Surgical Inc. (ISRG) rose 4.46% to $439.92, outperforming the mixed market on Monday. The stock's gain ended a two-day losing streak, despite the Dow Jones Industrial Average rising and the S&P 500 Index experiencing a slight dip.
NTRA's Signatera CDx Wins FDA Nod in Muscle-Invasive Bladder Cancer
Natera, Inc. (NTRA) announced that its Signatera CDx received FDA approval as a companion diagnostic for adjuvant atezolizumab immunotherapy in patients with muscle-invasive bladder cancer (MIBC). This marks the first companion diagnostic approval in blood-based minimal residual disease (MRD) testing and is expected to significantly advance personalized oncology care. The approval is supported by positive findings from the Phase III IMvigor011 trial, which demonstrated improved outcomes for MRD-positive patients and the potential for personalized treatment decisions for MRD-negative patients.
CVRx Stock Up on Humana's Medicare Coverage for Barostim Therapy
CVRx stock rose after Humana announced Medicare Advantage coverage for its Barostim therapy, effective May 1, 2026. This policy expands patient access to the heart failure treatment and covers both FDA-approved indications and patients in the BENEFIT-HF trial. The news follows other favorable reimbursement developments earlier in 2026 and is expected to strengthen CVRx's commercial position and drive future revenue growth in the neuromodulation devices market.
Intuitive Surgical, Inc. Stock 12‑Month Price Target Cut to $577.87, Implies 37% Upside
Analyst estimates for Intuitive Surgical, Inc. (ISRG) have led to a reduced average 12-month price target of $577.87, down from $582.35. Despite this cut, the new target still suggests a 37% potential upside from its May 15 closing price. The consensus rating for ISRG remains a "Buy" among 38 analysts.
TFX News | TELEFLEX INC (NYSE:TFX)
This article provides recent news and analysis for Teleflex Inc. (NYSE:TFX), including its current stock price and performance related to Q1 estimates, Q4 earnings, and a major divestiture plan. It also highlights the company's showcase of new clinical data for its UroLift™ System and Barrigel™ Rectal Spacer, and announces its quarterly dividend. Several entries from ChartMill also suggest TFX as a compelling value investment with strong fundamentals.
North Dakota State Investment Board Invests $6.93 Million in Intuitive Surgical, Inc. $ISRG
The North Dakota State Investment Board has acquired a new position in Intuitive Surgical, Inc. (NASDAQ:ISRG), purchasing 12,238 shares valued at approximately $6.93 million. This comes amidst other hedge funds adjusting their stakes in the medical equipment provider, and various analyst reports and positive sentiment regarding Intuitive Surgical's integration of AI in healthcare and the performance of its da Vinci 5 system.
PROCEPT BioRobotics Corporation (NASDAQ:PRCT) Receives Average Recommendation of "Hold" from Brokerages
PROCEPT BioRobotics (NASDAQ:PRCT) has received a consensus "Hold" rating from 14 research firms, with an average 1-year price target of $41.45. The company recently reported Q1 revenue of $83.13 million, exceeding estimates, though EPS was slightly worse than expected at -$0.56. Insider activity showed mixed signals, with a director purchasing shares and an EVP selling some, while institutional ownership remains high.
Gabelli Funds LLC Reduces Stake in Intuitive Surgical, Inc. $ISRG
Gabelli Funds LLC significantly decreased its stake in Intuitive Surgical, Inc. by 5.8% in Q4, selling 4,086 shares and holding 66,394 shares valued at $37.6 million. Despite this reduction and some insider selling, analyst sentiment for ISRG remains largely positive with a "Moderate Buy" consensus and a $581.91 price target, following stronger-than-expected Q1 earnings of $2.50 EPS on $2.77 billion revenue. The article also highlights the company's stock performance, institutional activity, and the impact of AI on surgical robotics.
The Global Price of Progress: The Geography of Robotic Surgery
Robotic surgery is rapidly adopted in the U.S. and other wealthy nations but is significantly less accessible in low-income countries due to high costs and lack of infrastructure. This disparity creates a two-tiered healthcare system, leading to medical tourism for those who can afford it and potentially leaving patients in underserved areas with limited surgical options. The increasing competition from new robotic surgery systems post-patent expiration might eventually drive down costs, but it remains uncertain whether this will make the technology universally available.
Alcon Inc. stock (CH0432492467): eye-care specialist in focus after quarterly earnings
Alcon Inc. recently released new quarterly figures and updated its full-year outlook, bringing renewed attention to the eye-care specialist's stock among international and US investors. The company, headquartered in Switzerland but also listed on the NYSE, offers a business model combining surgical equipment, consumables, and vision-care products. Key drivers include aging demographics and innovation in ophthalmology, though competition and currency fluctuations impact its operations.
LENSAR Inc stock (US52634T1034): laser eye surgery specialist in focus after latest business updates
LENSAR Inc, a medical technology company specializing in femtosecond laser systems for cataract surgery, is being highlighted for its recent business developments, particularly the commercial rollout of its ALLY Adaptive Cataract Treatment System. The company's revenue model combines system sales with recurring procedure-based fees from consumables. LENSAR operates in a competitive market driven by an aging population and relies on surgeon adoption and patient willingness to pay for premium options, especially within the US healthcare system.
Skillsoft Corp. Class A Common Stock (NY: SKIL
This page provides news and financial information for Skillsoft Corp. Class A Common Stock (NYSE:SKIL), including its latest stock price, recent financial results, and details about its acquisition of Codecademy. It also lists various reports of stocks hitting 52-week lows, some of which reference Skillsoft, and press releases regarding Skillsoft's business developments and partnerships.
Medtronic PLC $MDT Shares Sold by Saratoga Research & Investment Management
Saratoga Research & Investment Management slightly reduced its stake in Medtronic PLC by 1.3% in the fourth quarter, though the medical technology company remains a significant holding, representing about 5.8% of the fund’s portfolio. Despite some analyst target cuts and a downgrade from Weiss Ratings, Medtronic holds a "Moderate Buy" consensus rating with an average price target of $107.80. The company recently reported strong quarterly results, beating EPS and revenue estimates, and offers a quarterly dividend of $0.71, yielding 3.7%.
Hills Bank & Trust Co Sells 14,826 Shares of Zimmer Biomet Holdings, Inc. $ZBH
Hills Bank & Trust Co significantly reduced its stake in Zimmer Biomet Holdings, Inc. by 64.9%, selling 14,826 shares and retaining 8,012 shares valued at $720,000. This divestment occurred despite Zimmer Biomet reporting better-than-expected Q4 earnings with an EPS of $2.09 against estimates of $1.86, and revenue of $2.09 billion, increasing 9.3% year-over-year. Analysts remain cautious, holding an average "Hold" rating with a consensus price target of $102.80, and several firms recently trimmed their price targets.
